Revance Therapeutics reported $4.47M in Trade Debtors for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Trade Debtors Change
Abbvie ABBV:US $ 10733M 756M
Aerie Pharmaceuticals AERI:US $ 63.62M 95.21M
Bristol Myers Squibb BMY:US $ 8511M 858M
Cara Therapeutics CARA:US $ 3.63M 2.48M
Coherus Biosciences CHRS:US $ 117.04M 5.98M
Eli Lilly And LLY:US $ 7805.7M 321.5M
Endo International Ordinary Shares ENDP:US $ 485.66M 116.38M
Horizon Pharma HZNP:US $ 684.51M 51.73M
JAZZ PHA JAZZ:US $ 572.39M 9.03M
Johnson & Johnson JNJ:US $ 15594M 311M
Merk MRK:US $ 9828M 598M
Pacira Pharmaceuticals PCRX:US $ 92.1M 4.22M
Procter & Gamble PG:US $ 5513M 272M
Revance Therapeutics RVNC:US $ 4.47M 1.12M
Supernus Pharmaceuticals SUPN:US $ 145.15M 3.78M
Teva Pharmaceutical Industries TEVA:US $ 4253M 276M